{"id":61039,"date":"2024-02-28T07:21:56","date_gmt":"2024-02-28T07:21:56","guid":{"rendered":"https:\/\/medsname.com\/ursodec\/"},"modified":"2026-04-30T10:23:39","modified_gmt":"2026-04-30T10:23:39","slug":"ursodec","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/ursodec\/","title":{"rendered":"Ursodec"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:0 0 18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Snelle antwoord<\/h3>\n<p><strong>Ursodec<\/strong> bevat <strong>ursodeoxycholic acid (UDCA) 150 mg<\/strong> per tablet \u2014 the first-line oral therapy for primary biliary cholangitis (PBC) and the main oral option for dissolving cholesterol gallstones. Typical adult dose is 13\u201315 mg\/kg\/day in divided doses with meals for PBC, 8\u201310 mg\/kg\/day for gallstone dissolution. Higher dose tablets (Udiliv 300mg) reduce pill burden.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f6f8;border:1px solid #e1e4e8;border-radius:4px;padding:14px 18px;margin:18px 0;display:flex;flex-wrap:wrap;gap:14px;font-size:0.95em;\"><span>\u2705 <strong>WHO-GMP gecertificeerd<\/strong> fabrikant<\/span><span>\ud83d\udce6 <strong>Discrete verpakking<\/strong><\/span><span>\ud83c\udf0d <strong>Wereldwijde verzending<\/strong><\/span><span>\ud83d\udcac <a href=\"\/nl\/reviews\/\">1.400+ klantbeoordelingen<\/a><\/span><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<h2>What ursodeoxycholic acid is<\/h2>\n<p>Ursodeoxycholic acid (UDCA, also called ursodiol) is a naturally occurring secondary bile acid. Therapeutically it does three things at once: it <strong>displaces cytotoxic hydrophobic bile acids<\/strong> (chenodeoxycholic, deoxycholic, lithocholic) from the bile-acid pool, it <strong>reduces biliary cholesterol secretion<\/strong> (which dissolves cholesterol gallstones over months), and it <strong>protects cholangiocytes<\/strong> from bile-acid-mediated injury through cytoprotective and immunomodulatory effects. It is the only oral therapy with mortality and transplant-free survival benefit in primary biliary cholangitis (Poupon 1991, 1994; meta-analyses 2002, 2014).<\/p>\n<h2>Indicaties<\/h2>\n<ul>\n<li><strong>Primaire biliaire cholangitis (PBC)<\/strong> \u2014 first-line therapy; 13\u201315 mg\/kg\/day in divided doses with meals. ~60\u201370% biochemical response (alkaline phosphatase normalisation or significant fall) over 12 months. Non-responders are switched or augmented with obeticholic acid or fibrates.<\/li>\n<li><strong>Cholesterol gallstone dissolution<\/strong> \u2014 for radiolucent stones &lt; 15 mm in a functioning gallbladder, in patients who cannot or will not have cholecystectomy. 8\u201310 mg\/kg\/day for 6\u201324 months. Stone recurrence after cessation is significant (\u2248 50% at 5 years).<\/li>\n<li><strong>Primary sclerosing cholangitis (PSC)<\/strong> \u2014 improves biochemistry; mortality benefit not proven. High-dose (28\u201330 mg\/kg\/day) is associated with worse outcomes and is contraindicated.<\/li>\n<li><strong>Intrahepatic cholestasis of pregnancy (ICP)<\/strong> \u2014 10\u201315 mg\/kg\/day (or 500 mg twice daily); reduces maternal pruritus and bile acid levels; may reduce fetal complications.<\/li>\n<li><strong>Niet-alcoholische leververvetting (NAFLD)<\/strong> \u2014 biochemistry improves but high-quality histological benefit is unproven; not a first-line NAFLD therapy in current guidelines.<\/li>\n<li><strong>Cystic fibrosis associated liver disease<\/strong> \u2014 used in paediatric and adult CF cholestasis.<\/li>\n<\/ul>\n<h2>Dosering<\/h2>\n<table>\n<thead>\n<tr>\n<th>Indicatie<\/th>\n<th>Dose (mg\/kg\/day)<\/th>\n<th>Schema<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>PBC<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 divided doses with meals<\/td>\n<\/tr>\n<tr>\n<td>Cholesterol gallstone dissolution<\/td>\n<td>8\u201310<\/td>\n<td>2 divided doses (with the largest dose at bedtime)<\/td>\n<\/tr>\n<tr>\n<td>PSC<\/td>\n<td>13\u201315 (do NOT exceed 28 mg\/kg)<\/td>\n<td>2\u20133 divided doses<\/td>\n<\/tr>\n<tr>\n<td>ICP (pregnancy)<\/td>\n<td>10\u201315<\/td>\n<td>2 divided doses<\/td>\n<\/tr>\n<tr>\n<td>NAFLD adjunct<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 divided doses<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Vermijd bij<\/h3>\n<ul>\n<li>Acute cholecystitis, cholangitis or biliary obstruction<\/li>\n<li>Calcified or pigment gallstones (no dissolution effect)<\/li>\n<li>Non-functioning gallbladder on oral cholecystography<\/li>\n<li>Severe hepatic decompensation (Child-Pugh C) \u2014 discuss with hepatology<\/li>\n<\/ul>\n<\/div>\n<h2>Bijwerkingen<\/h2>\n<p>Generally very well tolerated. Most common: mild diarrhoea (5\u201310%), abdominal discomfort, nausea, mild rash. Pruritus may transiently worsen in PBC during the first weeks before improving. Rarely: gallstone calcification (radio-opaque shift) on long courses.<\/p>\n<h2>Geneesmiddelinteracties<\/h2>\n<ul>\n<li><strong>Bile acid sequestrants (cholestyramine, colesevelam, colestipol)<\/strong> \u2014 bind UDCA in the gut and reduce absorption. Separate by \u2265 4\u20135 hours.<\/li>\n<li><strong>Aluminiumbevattende antacida<\/strong> \u2014 bind UDCA. Separate by \u2265 2 hours.<\/li>\n<li><strong>Oestrogens, oral contraceptives, clofibrate<\/strong> \u2014 increase biliary cholesterol saturation and antagonise the gallstone-dissolution effect.<\/li>\n<li><strong>Ciprofloxacin, dapsone<\/strong> \u2014 modestly altered absorption; clinically minor.<\/li>\n<\/ul>\n<h2>Zwangerschap en borstvoeding<\/h2>\n<p>Used routinely off-label in intrahepatic cholestasis of pregnancy with extensive safety data. Compatible with breastfeeding (excreted in trace amounts in milk; no infant harm reported).<\/p>\n<h2>Opslag<\/h2>\n<p>Store below 25 \u00b0C in a dry place, original packaging. Tablets are stable for the full labelled shelf life when kept dry.<\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Ursodec is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/nl\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Uw betalingsbeschrijving bij betaling per kaart toont de gereguleerde betalingsverwerker (een gereguleerde kaartbetalingverwerker), nooit \"MedsBase\" of een medicijnnaam.<\/p>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3>How long until I see results in primary biliary cholangitis?<\/h3>\n<p>Alkaline phosphatase typically falls within 4\u20138 weeks and the trajectory at 12 months predicts long-term outcome. The Toronto, Paris-1 and Paris-2 criteria define a &#8220;biochemical responder&#8221; at 1 year by ALP, AST and bilirubin thresholds. Non-responders should discuss obeticholic acid or fibrate add-on with hepatology.<\/p>\n<h3>Can UDCA dissolve any kind of gallstone?<\/h3>\n<p>Only cholesterol stones, only if radiolucent on imaging, only in a functioning gallbladder, and only if &lt; 15 mm. Calcified, pigment, or partially calcified stones do not respond.<\/p>\n<h3>Why does my doctor want me on UDCA forever for PBC?<\/h3>\n<p>PBC is a chronic autoimmune cholangitis. UDCA changes the disease trajectory but does not cure it. Stopping UDCA is followed by biochemical relapse within weeks. Lifelong therapy at 13\u201315 mg\/kg\/day is standard.<\/p>\n<h3>Kan ik het gebruiken tijdens de zwangerschap?<\/h3>\n<p>Yes \u2014 UDCA is the standard treatment for intrahepatic cholestasis of pregnancy. Decades of use show no fetal harm, and it reduces maternal pruritus and bile acid levels.<\/p>\n<h3>Will UDCA cause weight loss or weight gain?<\/h3>\n<p>Neither, in most patients. Mild diarrhoea may cause minor early weight loss in a small fraction.<\/p>\n<h3>Does UDCA work for non-alcoholic fatty liver?<\/h3>\n<p>It improves biochemistry (ALT, AST). Whether it improves liver histology and outcomes is not established in large trials. Current NAFLD\/NASH guidelines do not recommend UDCA as routine therapy.<\/p>\n<h3>Can I drink alcohol on UDCA?<\/h3>\n<p>Most patients on UDCA have an underlying liver condition. Alcohol is best avoided altogether in PBC, PSC and significant hepatic disease.<\/p>\n<h3>What is the difference between UDCA and bile salts in supplements?<\/h3>\n<p>UDCA is a specific bile acid (ursodeoxycholic). Generic &#8220;bile salt&#8221; supplements are mixtures of natural bile acids without therapeutic dose standardisation. Only purified UDCA tablets are used clinically for PBC and gallstone dissolution.<\/p>\n<h3>How is UDCA monitored?<\/h3>\n<p>For PBC: ALP, ALT, AST, GGT, total bilirubin every 3 months for the first year, then 6-monthly. For gallstone dissolution: ultrasound at 6, 12, and 24 months to track stone size.<\/p>\n<h3>Can high-dose UDCA be harmful?<\/h3>\n<p>In primary sclerosing cholangitis, doses \u2265 28 mg\/kg\/day were associated with WORSE clinical outcomes (Lindor 2009 NEJM). Stick to 13\u201315 mg\/kg\/day in PSC and never escalate without specialist input.<\/p>\n<h2>Other Liver &#038; Hepatology Products<\/h2>\n<ul>\n<li><a href=\"\/nl\/udiliv\/\">Udiliv (UDCA 300 mg) \u2014 higher-strength UDCA, fewer tablets<\/a><\/li>\n<li><a href=\"\/nl\/hepatitis-medication\/\">All Hepatitis &amp; Liver Medications<\/a><\/li>\n<li><a href=\"\/nl\/hepcinat\/\">Hepcinat (sofosbuvir) \u2014 direct-acting antiviral for chronic HCV<\/a><\/li>\n<li><a href=\"\/nl\/myhep-all\/\">MyHep All (sofosbuvir + velpatasvir) \u2014 pan-genotypic HCV<\/a><\/li>\n<li><a href=\"\/nl\/celin\/\">Celin (vitamin C) \u2014 antioxidant adjunct<\/a><\/li>\n<li><a href=\"\/nl\/l-glutathione-250mg\/\">L-Glutathione 250 mg \u2014 antioxidant for hepatic redox support<\/a><\/li>\n<\/ul>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0 0 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Medische Disclaimer<\/h3>\n<p style=\"margin:0;\">Deze informatie is uitsluitend bedoeld voor educatieve doeleinden en is geen vervanging voor medisch advies. Raadpleeg altijd een gekwalificeerde zorgverlener voordat u met een medicatie begint, deze wijzigt of stopt.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u2705 Dissolves gallstones<br \/>\n\u2705 Protects liver cells<br \/>\n\u2705 Reduces bile toxicity<br \/>\n\u2705 Verbeterde leverfunctie<br \/>\n\u2705 Alleviates liver inflammation<\/p>\n<p>Ursodec contains Ursodeoxycholic Acid.<\/p>","protected":false},"featured_media":61040,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334],"product_tag":[4967,4728],"class_list":{"0":"post-61039","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_tag-ursodec","10":"product_tag-ursodeoxycholic-acid","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/61039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=61039"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/61040"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=61039"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=61039"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=61039"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=61039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}